Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
SRPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$73.05 - $173.25
Previous CloseN/A
Volume185.86K
Average Volume (3M)1.69M
Market Cap
$7.41B
Enterprise Value$12.74B
Total Cash (Recent Filing)$1.10B
Total Debt (Recent Filing)$1.33B
Price to Earnings (P/E)32.0
Beta0.73
Next Earnings
Apr 30, 2025EPS Estimate
1.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.38
Shares Outstanding97,032,074
10 Day Avg. Volume3,056,967
30 Day Avg. Volume1,685,912
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.78
Price to Cash Flow (P/CF)19.50
P/FCF Ratio21.30
Enterprise Value/Market Cap1.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.05
Enterprise Value/Ebitda41.68
Forecast
1Y Price Target
$171.28Price Target Upside132.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
---
Bulls Say, Bears Say
Bulls Say
Market PerceptionInvestors generally believe SRPT at the current price is 'cheap' and see it as a buying opportunity.
Product AdoptionManagement doesn't expect any change to payer coverage due to the fatal acute liver event, suggesting confidence in Elevidys's continued adoption.
Bears Say
Safety ConcernsUnfortunate patient death raises safety concerns.
Sales GuidanceThere is an expectation that Sarepta will not achieve the guidance of ≥160% growth in ELEVIDYS revenues, indicating potential financial challenges.
---
Ownership Overview
4.14% Insiders
30.64% Mutual Funds
32.38% Other Institutional Investors
12.73% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $73.05 and its highest was $173.25 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $7.41B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Apr 30, 2025 which is in 35 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Feb 26, 2025. The company reported $1.5 earnings per share for the quarter, missing the consensus estimate of $1.883 by -$0.383.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is 1.99.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 97,032,074 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of $1.5 in its last earnings report, missing expectations of $1.883. Following the earnings report the stock price went down -3.556%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in SRPT
---
Sarepta Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$171.28 (132.69% Upside)
$171.28 (132.69% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 92%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 357.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $248.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.15%
12-Months-Change
Fundamentals
Return on Equity
19.71%
Trailing 12-Months
Asset Growth
21.40%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
---
SRPT Company Deck
---
SRPT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflects a highly positive performance with record-breaking revenue growth, successful ELEVIDYS launch, and strong guidance for 2025. Although there are challenges related to insurance and manufacturing, the overall outlook remains robust due to strategic advancements and pipeline progress.Read More>---
SRPT Stock 12 Month Forecast
Average Price Target
$171.28
▲(132.69% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Vertex Pharmaceuticals
―
PTC Therapeutics
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering SRPT
1 Year
1 Year Success Rate
29/46 ratings generated profit
1 Year Average Return
+11.13%
reiterated a buy rating 5 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 63.04% of your transactions generating a profit, with an average return of +11.13% per trade.
---